Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
in vivo
Biotech
Novartis pens $7.8B deal for Abogen's in vivo autoimmune TCE
The deal, which includes up to $7.2 billion in milestones, comes weeks after Novartis paused an autoimmune CAR-T program over three deaths.
Nick Paul Taylor
Oct 2, 2026 4:24am
Cellectis cans allogeneic CAR-Ts to hop aboard in vivo bandwagon
Sep 14, 2026 5:26am
TScan axes 75% of staff to make room for solid tumor programs
Sep 2, 2026 10:46am
Lilly preps gene editor for ph. 2 after strong cholesterol cuts
May 25, 2026 8:45am
AstraZeneca in vivo data shows potential, despite patient death
Mar 27, 2026 11:00am
Inside Beam's 'big push' for in vivo gene editing
Jan 21, 2026 7:52am
